Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy PK, Kinetics and Safety of Aramchol in Nonalcoholic Steatohepatitis (NASH) With Open-Label Part

NCT04104321 is registered in ClinicalTrials.gov with Galmed Research and Development, Ltd. as lead sponsor.

NCT NCT04104321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04104321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy PK, Kinetics and Safety of Aramchol in Nonalcoholic Steatohepatitis (NASH) With Open-Label Part
Lead sponsor
Galmed Research and Development, Ltd.
Phase
Phase 3
Overall status
Suspended
Start date
September 23, 2019
Completion date
June 30, 2027
Enrollment
157 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis (nash)